NCT07470489 2026-04-16
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
M.D. Anderson Cancer Center
BioNTech SE
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia